Prediction of fragility fractures in men with prostate cancer under androgen deprivation therapy: the importance of a multidisciplinary approach using a mini-invasive diagnostic tool

Endocrine. 2024 Mar;83(3):594-596. doi: 10.1007/s12020-023-03613-2. Epub 2023 Dec 19.

Abstract

Bone fragility in men who are treated with androgen deprivation therapy (ADT) has a complex pathophysiology that differs from that of primary and post-menopausal osteoporosis. Fracture risk assessment based on bone mineral density (BMD) and Fracture Risk Assessment Tool (FRAX) score might not be effective in this patient setting, since high frequency of fragility fractures has been reported even in subjects with low FRAX risk and normal BMD. In this paper we want to emphasize the importance in the individual assessment of bone fragility and prediction of fractures by measuring parameters of bone quality, assessing morphometric vertebral fractures and evaluating body composition that in subjects under hormone-deprivation therapies can play a crucial role. Noteworthy, a single mini-invasive diagnostic tool, i.e., the dual energy x-ray absorptiometry (DXA) scan, offers the opportunity to evaluate reliably parameters of bone quality (e.g., trabecular bone score) and body composition, besides measurement of BMD and assessment of vertebral fractures by a morphometric approach. This article highlights the values and cost-effectiveness of this mini-invasive tool in the context of multidisciplinary approach to subjects with prostate cancer under ADTs.

Keywords: Androgen-deprivation therapy; Body composition; FRAX; Fractures; Prostate cancer.

MeSH terms

  • Absorptiometry, Photon
  • Androgen Antagonists / adverse effects
  • Androgens
  • Bone Density
  • Humans
  • Male
  • Osteoporotic Fractures* / etiology
  • Osteoporotic Fractures* / prevention & control
  • Prostatic Neoplasms* / drug therapy
  • Risk Assessment
  • Risk Factors
  • Spinal Fractures* / etiology

Substances

  • Androgen Antagonists
  • Androgens